ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a late-stage, clinical biotechnology company developing and commercializing products addressing degenerative diseases, today ...
This East Bay molecular diagnostics company shunned the traditional IPO route to go public on the market's first trading day of 2016. Its stock jumped on its first day of trading on Monday. An East ...
ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing cellular therapies for unmet medical needs, announced the pricing of ...
and its recently formed subsidiary BioTime Acquisition Corporation (BAC) jointly announced today that they have entered into a non-binding letter of intent for a $10 million investment from a private ...
Insurers including Chubb , Fidelis and Lloyd's were granted permission on Tuesday to appeal against a London court ruling in favour of the world's largest aircraft lessor AerCap over jets stuck in ...
* Biotime Inc - Biotime expects to file CE Mark application by end of this year with possible approval and launch next year * Biotime Inc - all Renevia transplants were shown to be well tolerated ...
When a U.S. soldier is wounded in combat, his lost blood is often replaced with Hextend®, a plasma expander developed by BioTime (www.biotimeinc.com). The high molecular weight plasma expander also is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results